Abstract
Background/Objectives
To study the mechanism of restoration of retinal photoreceptor ellipsoid zone (EZ), after intravitreal bevacizumab (IVB) therapy, in diabetic macular oedema (DMO).
Subjects/Methods
Forty-four consecutive patients aged 40–65 years having type 2 diabetes mellitus (DM) with DMO were prospectively recruited for IVB therapy. It comprised of three doses (1.25 mg in 0.05 ml) of IVB at monthly intervals. Patients with other ocular and systemic diseases affecting retinal vessels and earlier ophthalmological interventions were excluded. Visual acuity (logMAR VA) was recorded. Spectral domain optical coherence tomography (SD-OCT) was performed pre and post intervention. Central sub-foveal thickness (CST) and grades of disorganization of retinal inner layers (DRIL), external limiting membrane (ELM) and EZ were assessed. Data were statistically analysed on SPSS software. Clinical trials registry: CTRI/2019/03/018135.
Results
Mean logMAR VA decreased after IVB therapy from 1.78 ± 0.07 pre-intervention to 0.42 ± 0.05 post intervention (p < 0.001). Similarly, CST reduced from 354.23 ± 15.0 µm pre-intervention to 233.18 ± 7.88 µm post intervention (p < 0.001). Among qualitative variables, DRIL decreased from 93.2% pre-intervention to 13.6% post intervention. Likewise, global ELM disruption reduced from 81.8 to 9.1% and global EZ disruption reduced from 79.5 to 11.4%. ELM restoration preceded EZ restoration.
Conclusion
Anti-VEGF therapy restores the barrier effect of ELM. It causes ELM to restore first followed by EZ restoration in DMO.
Subject terms: Retinal diseases, Tomography, Chemotherapy
Introduction
Diabetic retinopathy (DR) affects 93 million people worldwide. Among them, 21 million have treatable form of diabetic macula oedema (DMO) [1]. Overall prevalence of DMO in DR is between 11 and 15% [1–3].
Hyperglycaemic state in diabetes mellitus (DM) results in formation of advanced glycation end products (AGEs) [4]. Formation of AGEs correlates with the glycaemic control of the patient [5]. AGEs stimulates vascular endothelial growth factor (VEGF) expression [6–8]. Multiple physiological and pathological effects i.e. angiogenesis, vascular hyperpermeability, initiation of DR-like vascular changes, antithrombotic or prothrombotic responses, and neuroprotection can be attributed to VEGF [9]. In our earlier study, an increase in the level of serum VEGF has been reported with an increase in the severity of DR [10].
Advances in spectral-domain optical coherence tomography (SD-OCT) technology have enhanced the understanding of morphological alterations in individual layers of retina and their association with various molecular mechanisms [9]. Increase in VEGF has been found to be related with increased central subfield thickness (CST), disruption of external limiting membrane (ELM) and ellipsoid zone (EZ) in DMO [10, 11]. Increased severity of DR has also been found to be associated with disorganization of retinal inner layers (DRIL) [12]. Presence of DRIL has been found to correlate with EZ disruption in DMO [13]. EZ and DRIL have been found to be predictors of visual acuity (VA) in centre-involved DMO [12, 14].
Anti-VEGFs are considered as the first-line treatment for DMO. Bevacizumab is a full-length humanized monoclonal antibody of 149 kDa. Administration of intravitreal anti-VEGF agents are associated with reduction in CST and improvement in VA [15–17]. Mori et al. [9] showed restoration of the foveal photoreceptors following administration of intravitreal ranibizumab in DMO.
We conducted a tertiary care, prospective, interventional study. This study was undertaken to study the mechanism of restoration of ELM and EZ after intravitreal bevacizumab (IVB) therapy in DMO for the first time.
Materials and methods
The study authors confirm adherence to the doctrines of the Declaration of Helsinki. This study was conducted after approval by Institutional Ethics Committee of King George’s Medical University, Lucknow, India. A written, informed, voluntary consent was obtained from all the study subjects. This study was registered with Clinical Trial Registry of India bearing the registration number: CTRI/2019/03/018135.
Patients
Study patients comprised of Type 2 DM. A total of 44 consecutive patients of DMO between aged of 40–65 were included. Patients who did not give consent or had any other ocular or systemic disease affecting retinal vessels were excluded from the study. Patients who had received previous intravitreal injections, lasers or surgical interventions were also omitted from the study. Sample size was calculated according to Charan Biswas formula-
Data collection
Patient’s age and sex were documented. All study subjects underwent detailed ophthalmological examination including fundus evaluation using slit lamp biomicroscope, and indirect ophthalmoscope. Fluorescein angiography and spectral domain optical coherence tomography (SD-OCT) examinations were also performed. Baseline data were recorded. The outcome measures of the study were logMAR VA and OCT parameters (CST, DRIL, ELM and EZ). CST was the quantitative parameter whereas DRIL, ELM and EZ were the qualitative parameters. The outcome measures were assessed at pre-intervention (baseline) and at monthly intervals after every dose of IVB (after first, second and third dose of IVB). SD-OCT parameter, CST, was assessed in micrometre (μm) whereas the qualitative parameters were assessed according to their grades of severity. In cases with bilateral involvement, eye with more severe DMO was included. The patients were administered three doses of IVB (1.25 mg/0.05 mL) at monthly intervals in the affected eye.
Spectral domain optical coherence tomography
The Cirrus HD-OCT (Carl Zeiss Meditech, Inc., CA, USA) was used. A macular cube (128 × 512) with horizontal and vertical 5-line raster scans, fovea-centred, was acquired.
Image Interpretation
The baseline SD-OCT image of each patient was compared with subsequent OCT images after injections. CST, grading of DRIL, and ELM and EZ disruption were noted.
DRIL was defined as the failure to ascertain any of four inner layers of the retina, namely, the ganglion cell layer-inner plexiform layer (GCL-IPL) complex, inner nuclear layer (INL) and outer plexiform layer (OPL) boundaries [12–14]. DRIL was graded as Grade 0: absence of DRIL, and Grade 1 presence of DRIL.
The ELM was demarcated as first hyper-reflective band, representative of the junctional complex between the glial Müller cells and photoreceptor cells [9]. ELM disruption was graded as grade 0: ELM intact, grade 1: focal disruption of ELM with localized sub-foveal involvement and grade 2: global disruption of ELM with generalized involvement within macular cube.
The EZ was demarcated as the hyper-reflective band below the ELM which clinically represents the photoreceptor integrity [9, 10]. Disruption of EZ was graded as grade 0: intact EZ, grade 1: focal disruption of EZ indicating localized sub-foveal involvement and grade 2: global disruption of EZ indicating generalized involvement within macular cube.
Collection of data was done at monthly interval. Pre and post intervention data, after third dose of IVB, were analysed. SD-OCT assessment of DRIL, ELM and EZ was done by two independent observers masked to the pre- or post-intervention status. Inter-observer correlation was computed by Spearman correlation coefficient.
Data analysis
Continuous data were depicted as mean ± SE (standard error of the mean). Discrete (categorical) data were depicted in numbers (n) and percentages (%). Continuous two independent groups were compared by Student’s t test. Continuous groups were compared by analysis of variance. and the significance of mean difference within (intra) and between (inter) the groups was done by Newman–Keuls post hoc test. This was performed after ascertaining normality by Shapiro–Wilk’s test and homogeneity of variance between groups by Levene’s test. Categorical groups were compared using chi-square (χ2) test. Pearson correlation analysis was done to assess association between the variables. A two-tailed (α = 2) p < 0.05 was considered statistically significant. Analyses were performed on SPSS software (Windows version 17.0 was used).
Results
The demographic characteristics of patients are summarized in Table 1. Qualitative variables before and after intervention are summarized in Table 2.
Table 1.
Demographic characteristics (Mean ± SE) of patients (n = 44).
| Variables | Mean ± SD |
|---|---|
| Age (years) | 54.36 ± 0.80 |
| Female | 20 |
| Male | 24 |
| HbA1c (%) | 6.10 ± 0.06 |
| Fasting blood sugar (mg/dl) | 89.00 ± 1.48 |
| Post-prandial blood sugar (mg/dl) | 128.50 ± 1.84 |
| Serum urea (mg/dl) | 30.38 ± 1.23 |
| Serum creatinine (mg/dl) | 1.50 ± 0.04 |
Table 2.
Qualitative variables before and after Interventions (n = 44).
| Variables | Total numbers (%) before intervention | Total numbers (%) after First Dose | Total numbers (%) after second dose | Total numbers (%) after intervention |
|---|---|---|---|---|
| DRIL | ||||
| Absent (Grade 0) | 3 (6.8) | 6 (13.6) | 30 (68.2) | 38 (86.4) |
| Present (Grade 1) | 41 (93.2) | 38 (86.4) | 14 (31.8) | 6 (13.6) |
| ELM | ||||
| No Disruption (Grade 0) | 0 (0.0) | 5 (11.4) | 29 (65.9) | 37 (84.1) |
| Focal Disruption (Grade 1) | 8 (18.2) | 12 (27.3) | 6 (13.6) | 3 (6.8) |
| Global Disruption (Grade 2) | 36 (81.8) | 27 (61.4) | 9 (20.5) | 4 (9.1) |
| EZ | ||||
| No Disruption (Grade 0) | 2 (4.5) | 3 (6.8) | 22 (50.0) | 35 (79.5) |
| Focal Disruption (Grade 1) | 7 (15.9) | 30 (68.2) | 14 (31.6) | 4 (9.1) |
| Global Disruption (Grade 2) | 35 (79.5) | 11 (25.0) | 8 (18.4) | 5 (11.4) |
It was observed that mean logMAR VA decreased significantly after IVB regimen from 1.78 ± 0.07 at baseline to 0.42 ± 0.05 (p < 0.001). Similar trend was observed in CST which decreased significantly from pre-treatment level of 354.23 ± 15.0 to 233.18 ± 7.88 post intervention (p < 0.001). SD-OCT assessment of DRIL, ELM, EZ was done. Inter-observer correlation was computed as 0.9. Amongst qualitative variables, DRIL was evident in majority of patients (93.2%) pre-intervention, which reduced to 13.6% after the IVB regimen. Similarly, global ELM disruption reduced from 81.8% pre-intervention to 61.4 % after first dose, 20.5% after second dose and finally 9.1% after third dose and global EZ disruption reduced from 79.5% pre-intervention to 25% after first dose, 18.4% after second dose and subsequently to 11.4% after IVB regimen (p < 0.001). It was observed that in the eyes in which ELM was restored, EZ was also restored after treatment. This was associated with corresponding decrease in logMAR VA. Figures 1, 2 shows complete restoration of ELM with partial restoration of EZ denoting that ELM restores first after anti-VEGF therapy.
Fig. 1. SD-OCT showing DRIL with disruption of ELM and EZ.
(Arrow marking DRIL).
Fig. 2. SD-OCT showing partial restoration of DRIL and complete restoration of ELM with EZ in the process of restoration following third dose of intravitreal anti-VEGF (Bevacizumab).
(Arrowhead marking ELM and arrow marking EZ).
Correlation of biochemical parameters, VA and OCT parameters before and after intervention, was done using Pearson correlation analysis. Significant positive correlation was found between CST and VA (r = 0.65), and this correlation increased after intervention suggesting the beneficial effect of IVB therapy (r = 0.93, p < 0.001).
Discussion
DRIL is defined as the failure to identify any of the boundaries of GCL-IPL complex, INL and OPL. Also, DRIL has been found to be a predictor of VA [14].
The EZ clinically defines the photoreceptor integrity. The biological EZ consists mainly of mitochondria. This enables higher levels of energy consumption within the photoreceptors. Focal or global absence of the EZ on SD-OCT corresponds to the reduced reflectivity or anatomic absence of the EZ. Dysfunction of mitochondria in the foveal photoreceptors results in reduced VA in DMO [9].
The ELM is defined as the junctional complex between the glial Müller cells and photoreceptor cells. It serves as a barrier against macromolecules [9]. Damage in the glial Müller cells might contribute to both ELM disruption as well as inner retinal thickening. The disrupted barrier properties in the ELM might dysregulate the fluid dynamics, concomitantly allowing accumulation of intraretinal or subretinal fluids [9].
In the present study, IVB therapy was associated with significant improvement in DRIL and restoration of ELM and EZ leading to decrease in logMAR VA.
Comyn et al. and Wells et al. found that there is significant reduction of CST and CAT in patients of DMO after anti-VEGF treatment [18, 19]. We also observed that CST significantly decreased after IVB therapy. Aiello et al. [20], Nguyen et al. [21] and Pelosini et al. [22] observed that the magnitude of CST reduction in several treatment regimens was associated with a better VA outcome. Our study also demonstrated similar findings.
We also observed that improvement in SD-OCT qualitative parameters comprising of DRIL, ELM and EZ were evident following intervention. Sun et al. suggested DRIL to be a strong predictor of VA in eyes with DMO. Therefore, DRIL can be used as a biomarker for predicting future VA [14]. We observed that improvement in VA was more evident in patients associated with improvement of DRIL. This suggests that restoration of DRIL is directly related to improvement in VA. DRIL has also been shown to correlate with EZ disruption [13]. DRIL is thought to correlate to regions where bipolar, horizontal, and amacrine cell synaptic connections have been disrupted, thus interrupting the transmission pathway between the ganglion cells and photoreceptors, leading to decrease in VA [12, 23]. Anti-VEGF therapy improves DRIL, thereby leading to restoration of synaptic connections and transmission of impulses from photoreceptors and resultant improvement of VA [9].
Similar significant findings were observed with regard to ELM and EZ disruption [10, 24]. Percentage disruption of EZ has been found to correlate with VA in DMO [12]. Integrity of ELM and EZ has been found to be a positive predictor for visual outcome [24–27]. Kang et al. demonstrated that the sturdiest predictor of final BCVA was the status of EZ integrity followed by status of ELM [28]. We observed that decrease in logMAR VA was more pronounced in patients which were associated with restoration of ELM and EZ. ELM restoration was observed in 84.1%, whereas, EZ restoration was seen in 79.4% after IVB.
Hareedy et al. [29] found that improvement in photoreceptor integrity took place after second and third dose of ranibizumab with improvement in VA and colour vision. They found a statistically significant relation between colour vision and EZ after the first injection, but the correlation after the second and third injections was much more significant. They also reported that improvement in BCVA significantly correlated with EZ after the second and third injection.
Achiron et al. [30] concluded that restoration of foveal photoreceptor microstructure following anti-VEGF therapy was associated with improvement in VA. A larger foveal photoreceptor microstructure defect was associated with lower VA. Patients with larger foveal photoreceptor microstructure defects at baseline had smaller VA improvements, and the improvement in foveal photoreceptor microstructure integrity was associated with VA improvement.
Chatzerelli et al. [31] also reported significant restoration of EZ photoreceptors in patients of DMO following intravitreal ranibizumab after 12 months follow-up. The improvement in EZ defect size was dependent on the pattern of DMO on SD-OCT.
Omri et al. [32] demonstrated in rat and monkey retina that ELM comprised of attachment of outer process of glial Muller cells to one another and also to inner photoreceptor segments. They also found that tight junctions (TJ) exist in the ELM. Ultrastructural analysis suggested that TJ exist between glial Muller cells and photoreceptors. Occludin, a protein, is a key component of TJ. Occludin is organized between the glial Muller cells and the photoreceptors at the ELM. They suggested that the ELM should be considered as part of a retinal barrier that may be disrupted in various pathological conditions. During diabetic retinopathy, not only are the glial Muller cells swollen but they also lose their occludin content at the ELM level. Hence, ELM junctions could be unique regulatory targets in treatment [32]. Murukami et al. [33] highlighted in primary bovine retinal endothelial cells that VEGF treatment induced occludin phosphorylation, ubiquitination and fragmentation of TJ. They demonstrated that occludin had a significant role in regulation of barrier properties and might serve as a possible therapeutic target. We also observed in our earlier SD-OCT based study that an increase in VEGF was associated with increased severity of DR and sequential ELM and EZ disruption, highlighting that an intact ELM was a prerequisite for an intact EZ in DMO [10, 24].
Our study provides insight into the mechanism of ELM and EZ restoration after anti-VEGF therapy. Anti-VEGF therapy led to restoration of barrier effect of ELM. The ELM was found to restore first followed by EZ restoration in DMO.
Summary
What was known before
Increase in VEGF levels is associated with ELM and EZ disruption in DMO.
After anti-VEGF therapy, decrease in macular thickness is associated with improvement in visual acuity in DMO.
After anti-VEGF therapy, improvement in DRIL and restoration of EZ occurs.
What this study adds
This study for the first time highlights the mechanism of EZ restoration.
Anti-VEGF therapy restores the barrier effect of ELM.
ELM restores first followed by EZ restoration in DMO.
An intact ELM is a prerequisite for an intact EZ in DMO.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Footnotes
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;3:152–60.. doi: 10.2337/dc11-1909. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Xie XW, Xu L, Wang YX, Jonas JB. Prevalence and associated factors of diabetic retinopathy. The Beijing eye study 2006. Graefes Arch ClinExpOphthalmol. 2008;246:1519–26. doi: 10.1007/s00417-008-0884-6. [DOI] [PubMed] [Google Scholar]
- 3.Wong TY, Klein R, Islam FM, Cotch MF, Folsom AR, Klein BE, et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol. 2006;141:446–55.. doi: 10.1016/j.ajo.2005.08.063. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Prasad K, Mishra M. AGE-RAGE stress, stressors, and antistressors in health and disease. Int J Angiol. 2018;27:1–12. doi: 10.1055/s-0037-1613678. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Sharma Y, Saxena S, Mishra A, Saxena A, Natu SM. Advanced glycation end products and diabetic retinopathy. J OculBiol Dis Info. 2013;5:63–9. doi: 10.1007/s12177-013-9104-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Yamagishi S, Inagaki Y, Amano S, Okamoto T, Takeuchi M, Makita Z. Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product induced injury through its antioxidative properties. BiochemBiophys Res Commun. 2002;296:877–82. doi: 10.1016/S0006-291X(02)00940-3. [DOI] [PubMed] [Google Scholar]
- 7.Lu M, Kuroki M, Amano S, Tolentino M, Keough K, Kim I. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest. 1998;101:1219–24. doi: 10.1172/JCI1277. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Pusparajah P, Lee LH, Kadir AK. Molecular markers of diabetic retinopathy: potential screening tool of the future. Front Physiol. 2016;7:200–1. doi: 10.3389/fphys.2016.00200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Mori Y, Suzuma K, Uji A, Ishihara K, Yoshitake S, Fujimoto M, et al. Restoration of foveal photoreceptors after intravitreal ranibizumab injections for diabetic macular edema. Sci Rep. 2016;6:3–5. doi: 10.1038/s41598-016-0007-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Jain A, Saxena S, Khanna VK, Shukla RK, Meyer CH. Status of serum VEGF and ICAM-1 and its association with external limiting membrane and inner segment-outer segment junction disruption in type 2 diabetes mellitus. Mol Vis. 2013;19:1760–8. [PMC free article] [PubMed] [Google Scholar]
- 11.Sharma SR, Saxena S, Mishra N, Akduman L, Meyer CH. The association of grades of photoreceptor inner segment-ellipsoid band disruption with severity of retinopathy in type 2 diabetes mellitus. J Case Rep Stud. 2014;2:502–8. [Google Scholar]
- 12.Maheshwary AS, Oster SF, Yuson RM, Cheng L, Mojana F, Freeman WR. The association between percent disruption of the photoreceptor inner segment-outer segment junction and visual acuity in diabetic macular edema. Am J Ophthalmol. 2010;150:63–7. doi: 10.1016/j.ajo.2010.01.039. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Nadri G, Saxena S, Stefanickova J, Ziak P, Benacka J, Gilhotra JS, et al. Disorganization of retinal inner layers correlates with ellipsoid zone disruption and retinal nerve fiber layer thinning in diabetic retinopathy. J Diab Compl. 2019;33:550–3. doi: 10.1016/j.jdiacomp.2019.05.006. [DOI] [PubMed] [Google Scholar]
- 14.Sun JK, Lin MM, Lammer J, Prager S, Sarangi R, Silva PS, et al. Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema. JAMA Ophthalmol. 2014;132:1309–16. doi: 10.1001/jamaophthalmol.2014.2350. [DOI] [PubMed] [Google Scholar]
- 15.Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin®) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2005;36:336–39.. doi: 10.3928/1542-8877-20050701-15. [DOI] [PubMed] [Google Scholar]
- 16.Kriechbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenauer W, et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol. 2008;92:518–22. doi: 10.1136/bjo.2007.127282. [DOI] [PubMed] [Google Scholar]
- 17.Priglinger SG, Wolf AH, Kreutzer TC, Kook D, Hofer A, Strauss RW, et al. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina. 2007;27:1004–12. doi: 10.1097/IAE.0b013e3180ed458d. [DOI] [PubMed] [Google Scholar]
- 18.Comyn O, Sivaprasad S, Peto T, Neveu MM, Holder GE, Xing W, et al. A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study) Am J Ophthalmol. 2014;157:960–70. doi: 10.1016/j.ajo.2014.02.019. [DOI] [PubMed] [Google Scholar]
- 19.Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193–203. doi: 10.1056/NEJMoa1414264. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Aiello LP, Edwards AR, Beck RW, Bressler NM, Davis MD, Ferris F, et al. Diabetic Retinopathy Clinical Research Network Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2010;117:946–95. doi: 10.1016/j.ophtha.2009.10.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. RISE and RIDE Research Group Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789–801. doi: 10.1016/j.ophtha.2011.12.039. [DOI] [PubMed] [Google Scholar]
- 22.Pelosini L, Hull CC, Boyce JF, McHugh D, Stanford MR, Marshall J. Optical coherence tomography may be used to predict visual acuity in patients with macular edema. Invest Ophthalmol Vis Sci. 2011;52:2741–48. doi: 10.1167/iovs.09-4493. [DOI] [PubMed] [Google Scholar]
- 23.Saxena S, Srivastav K, Cheung CM, Ng JY, Lai TY. Photoreceptor inner segment ellipsoid band integrity on spectral domain optical coherence tomography. ClinOphthalmol. 2014;8:2507–22. doi: 10.2147/OPTH.S72132. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Saxena S, Ruia S, Prasad S, Jain A, Mishra N, Natu SM, et al. Increased serum levels of urea and creatinine are surrogate markers for disruption of retinal photoreceptor external limiting membrane and inner segment ellipsoid zone in type 2 diabetes mellitus. Retina. 2017;37:344–49.. doi: 10.1097/IAE.0000000000001163. [DOI] [PubMed] [Google Scholar]
- 25.Theodossiadis PG, Theodossiadis GP, Charonis A, Emfietzoglou I, Grigoropoulos VG, Liarakos VS. The photoreceptor layer as a prognostic factor for visual acuity in the secondary epiretinal membrane after retinal detachment surgery: Imaging analysis by spectral-domain optical coherence tomography. AmJOphthalmol. 2011;151:973–80. doi: 10.1016/j.ajo.2010.12.014. [DOI] [PubMed] [Google Scholar]
- 26.Kwon Y, Lee D, Kim H, Kwon O. Predictive findings of visual outcome in spectral domain optical coherence tomography after ranibizumab treatment in age-related macular degeneration. Korean J Ophthalmol. 2014;28:386–92. doi: 10.3341/kjo.2014.28.5.386. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Uji A, Murakami T, Nishijima K, Akagi T, Horii T, Arakawa N, et al. Association between hyperreflective foci in the outer retina, status of photoreceptor layer, and visual acuity in diabetic macular edema. Am J Ophthalmol. 2012;153:710–17. doi: 10.1016/j.ajo.2011.08.041. [DOI] [PubMed] [Google Scholar]
- 28.Kang HM, Chung EJ, Kim YM, Koh HJ. Spectral-domain optical coherence tomography (SD-OCT) patterns and response to intravitreal bevacizumab therapy in macular edema associated with branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2013;251:501–8. doi: 10.1007/s00417-012-2067-8. [DOI] [PubMed] [Google Scholar]
- 29.Hareedy NH, Gaafar AA, El-Dayem HK, El-Shinawy RF. The relation between inner segment/outer segment junction and visual acuity before and after ranibizumab in diabetic macular edema. J Egypt Ophthalmol Soc. 2018;111:102–7. doi: 10.4103/ejos.ejos_26_18. [DOI] [Google Scholar]
- 30.Achiron A, Kydyrbaeva A, Man V, et al. Photoreceptor integrity predicts response to anti-VEGF treatment. Ophthalmic Res. 2017;57:37–41. doi: 10.1159/000448522. [DOI] [PubMed] [Google Scholar]
- 31.Chatziralli I, Theodossiadis G, Dimitriou E, Kazantzis D, Theodossiadis P. Association between the patterns of diabetic macular edema and photoreceptors’ response after intravitreal ranibizumab treatment: a spectral-domain optical coherence tomography study. Int Ophthalmol. 2020 doi: 10.1007/s10792-020-01423-3. [DOI] [PubMed] [Google Scholar]
- 32.Omri S, Omri B, Savoldelli M, Jonet L, Thillaye-Goldenberg B, Thuret G, et al. The outer limiting membrane (OLM) revisited: clinical implications. ClinOphthalmol. 2010;4:183–95. doi: 10.2147/opth.s5901. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Murukami T, Felinski EA, Antonetti DA. Occludin phosphorylation and ubiquitination regulate tight junction trafficking and vascular endothelial growth factor (VEGF)-induced permeability. J Biol Chem. 2009;284:21036–46. doi: 10.1074/jbc.M109.016766. [DOI] [PMC free article] [PubMed] [Google Scholar]